Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30137692 | 0.91 | MAPT (0.41) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1656059 | 0.91 | MAPT (0.41) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL82689 | 0.90 | MAPT (0.45) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL12533506 | 0.90 | MAPT (0.45) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL6730444 | 0.90 | MAPT (0.39) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1497638 | 0.90 | MAPT (0.39) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL14883303 | 0.89 | THRB (0.43) | ALDH1A1SMN1; SMN2KDM4ECYP1A2MEN1 | |
| SCHEMBL1658265 | 0.89 | MAPT (0.38) | MAPTMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL30137686 | 0.89 | RAB9A (0.45) | MAPTALDH1A1SMN1; SMN2POLBKDM4E | |
| SCHEMBL1655443 | 0.89 | RAB9A (0.45) | MAPTALDH1A1SMN1; SMN2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038285-A | Kit and method for constructing human bone organ by using pluripotent stem cells | 广东医科大学附属医院 | 2026-05-15 | — | — | CN | claimed |
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210353605-A1 | METHODS FOR TREATING ORAL CANCERS | CHANG GUNG UNIVERSITY (TW) | 2021-11-18 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2014083327-A1 | ADENINE DERIVATIVES SUITABLE FOR THE TREATMENT OF (INTER ALIA) MUSCULAR DYSTROPHY | MD PHARMA AB (SE) | 2014-06-05 | — | — | WO | claimed |
| WO-2013049581-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20120231015-A1 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-09-13 | — | — | US | claimed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| WO-2011056930-A2 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2011-05-12 | — | — | WO | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | MAPT 1321/4885MAPK1 4399/4885ALDH1A1 2807/4885 |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | MAPT 1562/4885MAPK1 478/4885ALDH1A1 3902/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | MAPT 1939/4885MAPK1 1785/4885ALDH1A1 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.